Equities

PureTech Health PLC

PRTC:LSE

PureTech Health PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)219.00
  • Today's Change5.00 / 2.34%
  • Shares traded837.60k
  • 1 Year change0.23%
  • Beta1.1847
Data delayed at least 20 minutes, as of May 03 2024 16:45 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year PureTech Health PLC's revenues fell -78.68% from 15.62m to 3.33m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 50.35m to a larger loss of 65.70m.
Gross margin--
Net profit margin-2,000.84%
Operating margin-2,534.90%
Return on assets-9.54%
Return on equity-13.06%
Return on investment-10.67%
More ▼

Cash flow in USDView more

In 2023, PureTech Health PLC increased its cash reserves by 27.50%, or 41.22m. Cash Flow from Financing totalled 78.14m or 2,346.58% of revenues. In addition the company used 105.92m for operations while cash from investing totalled 68.99m.
Cash flow per share-0.1767
Price/Cash flow per share--
Book value per share1.36
Tangible book value per share1.36
More ▼

Balance sheet in USDView more

PureTech Health PLC has a Debt to Total Capital ratio of 5.24%, a lower figure than the previous year's 6.34%.
Current ratio6.76
Quick ratio--
Total debt/total equity0.0546
Total debt/total capital0.0524
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.